This bill introduces a new section to RSA 420-B that mandates health maintenance organizations (HMOs) to utilize the lowest cost method for reimbursing clinician-administered drugs. It defines "clinician-administered drugs" as outpatient prescription drugs that cannot be reasonably self-administered and are typically administered by a healthcare professional in clinical settings. The bill also requires HMOs to cover these drugs if they are dispensed by in-network hospitals or clinics, provided that the medication is needed more urgently than through other channels.

Additionally, the bill prohibits HMOs from requiring pharmacies to dispense clinician-administered drugs directly to patients with the expectation that they will transport the medication to a healthcare setting for administration. This practice, known as "brown-bagging," is seen as potentially increasing costs for insurers, which may lead to higher insurance premiums. The effective date for this act is set for January 1, 2026.